Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
332.54
-2.52 (-0.75%)
Sep 30, 2026, 4:00 PM EDT - Market closed
Krystal Biotech Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 9,860 | 7,149 | 4,506 | 3,499 | 2,040 | 1,742 | |
Market Cap Growth | 102.99% | 58.67% | 28.76% | 71.56% | 17.08% | 47.34% |
Enterprise Value | 8,766 | 6,294 | 3,819 | 2,909 | 1,642 | 1,388 |
Last Close Price | 335.06 | 246.54 | 156.66 | 124.06 | 79.22 | 69.95 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 41.97 | 34.90 | 50.54 | 320.10 | - | - |
Forward PE | 40.40 | 34.89 | 33.31 | - | - | - |
PS Ratio | 22.52 | 18.37 | 15.51 | 69.02 | - | - |
PB Ratio | 7.30 | 5.86 | 4.76 | 4.49 | 3.91 | 2.94 |
P/TBV Ratio | 7.30 | 5.86 | 4.76 | 4.49 | 3.91 | 2.94 |
P/FCF Ratio | 38.48 | 37.84 | 37.81 | - | - | - |
P/OCF Ratio | 36.43 | 35.59 | 36.51 | - | - | - |
PEG Ratio | 0.93 | 0.61 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 20.04 | 16.18 | 13.15 | 57.38 | - | - |
EV/EBITDA Ratio | 44.29 | 38.64 | 36.12 | - | - | - |
EV/EBIT Ratio | 44.63 | 39.02 | 36.99 | - | - | - |
EV/FCF Ratio | 34.24 | 33.32 | 32.04 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 |
Debt / EBITDA Ratio | 0.04 | 0.06 | 0.07 | - | - | - |
Debt / FCF Ratio | 0.03 | 0.05 | 0.06 | - | - | - |
Net Debt / Equity Ratio | -0.80 | -0.78 | -0.78 | -0.75 | -0.72 | -0.83 |
Net Debt / EBITDA Ratio | -5.49 | -5.81 | -7.02 | 6.29 | 3.16 | 7.37 |
Net Debt / FCF Ratio | -4.24 | -5.01 | -6.23 | 5.83 | 2.44 | 4.25 |
Asset Turnover | 0.33 | 0.33 | 0.31 | 0.07 | - | - |
Inventory Turnover | 0.62 | 0.69 | 1.20 | - | - | - |
Quick Ratio | 7.73 | 9.28 | 6.89 | 17.35 | 13.14 | 17.02 |
Current Ratio | 8.32 | 9.95 | 7.28 | 17.77 | 13.30 | 17.18 |
Return on Equity (ROE) | 20.12% | 18.91% | 10.34% | 1.68% | -25.09% | -15.71% |
Return on Assets (ROA) | 9.37% | 8.44% | 6.89% | -8.82% | -12.80% | -9.32% |
Return on Invested Capital (ROIC) | 40.16% | 42.60% | 31.62% | -40.50% | -76.89% | -74.23% |
Return on Capital Employed (ROCE) | 14.40% | 13.10% | 10.80% | -12.40% | -22.90% | -11.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.43% | 2.86% | 1.98% | 0.31% | -6.86% | -3.99% |
FCF Yield | 2.60% | 2.64% | 2.65% | -2.88% | -7.53% | -6.67% |
Buyback Yield / Dilution | -1.46% | -0.71% | -7.16% | -8.87% | -14.85% | -18.15% |